Close Menu

NEW YORK (360Dx) – Co-Diagnostics said this week it has closed a non-convertible debt instrument for $2 million. The firm will use the funds for working capital, to expand distribution of its infectious disease testing products, and to accelerate initiatives to develop multiplex screens for liquid biopsy cancer screening, blood-bank screening, and SNP detection with applications in several areas.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.